CVOT

Quick definition. A cardiovascular outcomes trial (CVOT) is a large, long study that measures whether a medication prevents — or causes — heart attacks, strokes, and cardiovascular death. CVOTs are the reason some GLP-1 drugs can claim heart benefits, not just blood-sugar or weight benefits.

What a CVOT Is

A cardiovascular outcomes trial is a randomized study designed specifically to measure a drug's effect on hard cardiovascular events rather than on a surrogate marker like blood sugar. The primary endpoint is usually "MACE" — major adverse cardiovascular events — typically defined as the combination of cardiovascular death, non-fatal heart attack, and non-fatal stroke. CVOTs enroll thousands of participants and follow them for several years, because these events are individually uncommon and a large sample over a long period is needed to detect a real difference.

Why They Became Required

CVOTs rose to prominence after an earlier diabetes drug raised concerns about cardiovascular harm in the late 2000s. In response, the FDA issued 2008 guidance requiring manufacturers of new type 2 diabetes drugs to demonstrate that the drug did not pose an unacceptable cardiovascular risk — effectively mandating a CVOT for the class. This requirement reshaped diabetes drug development for over a decade. In 2020 the FDA updated its guidance, moving away from a blanket CVOT mandate toward a broader assessment of safety, but the trials run under the original framework had by then produced a wealth of outcome data.

What GLP-1 CVOTs Found

Several GLP-1 receptor agonists did far more than prove safety — they demonstrated cardiovascular benefit. The LEADER trial showed liraglutide (Victoza) reduced major cardiovascular events in people with type 2 diabetes and high cardiovascular risk, and REWIND showed a similar benefit for dulaglutide (Trulicity), including in a lower-risk population. On the strength of these results, several GLP-1 medications earned FDA indications for reducing cardiovascular risk — claims that rest directly on CVOT evidence.

The SELECT Trial: Beyond Diabetes

A landmark step came with the SELECT trial, which studied semaglutide (Wegovy) in adults who had established cardiovascular disease and overweight or obesity but did not have diabetes. SELECT found that semaglutide reduced major adverse cardiovascular events by roughly 20% compared with placebo. This was the first time a weight-management GLP-1 medication demonstrated cardiovascular benefit in people without diabetes, and it supported an expanded FDA indication for cardiovascular risk reduction in that population — extending the relevance of CVOT evidence well beyond diabetes care.

How to Read CVOT Claims

When a comparison or drug page notes that a medication "reduces cardiovascular risk," that statement should trace back to a specific CVOT and the population it studied. The benefit demonstrated in a trial of high-risk patients with established disease does not automatically apply to everyone, and results from one drug do not transfer to another. CVOTs are also where SGLT2 inhibitors established their distinct heart-failure and kidney benefits. Understanding that these claims are grounded in named, published outcome trials — rather than in surrogate measures — is key to interpreting them accurately.